Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.0102/japi.2021.07 http://scihub22266oqcxt.onion/10.0102/japi.2021.07 34431263!ä!34431263 Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=34431263&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Assoc+Physicians+India 2021 ; 69 (7): 14-19 Nephropedia Template TP {{tp|p=34431263|t=2021. Clinical Study of Use of Remdesivir and Tocilizumab in Severely Ill COVID-19 Patients |pdf=|usr=}}{{34431263}} gab.com Text Clinical Study of Use of Remdesivir and Tocilizumab in Severely Ill COVID-19 Patients JO: J Assoc Physicians India http://www.kidney.de/pget.php?&tw=1&pmid=34431263 #FOAvip INTRODUCTION: Remdesivir and Tocilizumab are two experimental drugs used in severely ill COVID-19 patients. Various clinical trials studying these drugs are giving conflicting results. Our aim is to study these two drugs and share the experience in our setting. METHODS: Our Study is a retrospective analysis of Clinico-laboratory details and outcome of three groups of patients who were given either (i) Remdesivir or (ii) Tocilizumab or (iii)both Remdesivir and Tocilizumab . We compared the outcome of these patients with other patients who did not receive either of these drugs, when it was not available or not introduced as experimental drugs earlier in treatment guidelines. RESULTS: Out of a total of 521 patients, in the above three groups who received either or both Remdesivir or Tocilizumab, 334 survived. Out of 214 patients who did not receive any of the two drugs only 74 survived. The outcome was better individually for all the three groups of patients receiving either or both of the drugs as compared to neither of the drugs.(p <0.01) CONCLUSION: Remdesivir and Tocilizumab were useful drugs in treatment of severely ill covid -19 patients as compared with the patients who did not receive any of the above drugs. Twit Text FOAVip Clinical Study of Use of Remdesivir and Tocilizumab in Severely Ill COVID-19 Patients ????J Assoc Physicians India http://www.kidney.de/pget.php?&tw=1&pmid=34431263 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34431263 #FOAvip English Wikipedia <ref>{{Cite pmid|34431263}}</ref> Clinical Study of Use of Remdesivir and Tocilizumab in Severely Ill COVID-19 Patients #MMPMID34431263 Gupta V; Ingawale S; Bhondve A; Khot W; Salagre S; Sonawale A; Joshi K; Vaidya M; Tiwari S; Salagre K; Pawade Y; Kawale J; Sabnis N J Assoc Physicians India 2021[Jul]; 69 (7): 14-19 PMID34431263show ga INTRODUCTION: Remdesivir and Tocilizumab are two experimental drugs used in severely ill COVID-19 patients. Various clinical trials studying these drugs are giving conflicting results. Our aim is to study these two drugs and share the experience in our setting. METHODS: Our Study is a retrospective analysis of Clinico-laboratory details and outcome of three groups of patients who were given either (i) Remdesivir or (ii) Tocilizumab or (iii)both Remdesivir and Tocilizumab . We compared the outcome of these patients with other patients who did not receive either of these drugs, when it was not available or not introduced as experimental drugs earlier in treatment guidelines. RESULTS: Out of a total of 521 patients, in the above three groups who received either or both Remdesivir or Tocilizumab, 334 survived. Out of 214 patients who did not receive any of the two drugs only 74 survived. The outcome was better individually for all the three groups of patients receiving either or both of the drugs as compared to neither of the drugs.(p <0.01) CONCLUSION: Remdesivir and Tocilizumab were useful drugs in treatment of severely ill covid -19 patients as compared with the patients who did not receive any of the above drugs. |*COVID-19 Drug Treatment[MESH] |Adenosine Monophosphate/analogs & derivatives[MESH] |Alanine/analogs & derivatives[MESH] |Antibodies, Monoclonal, Humanized[MESH] |Humans[MESH] |Retrospective Studies[MESH]Clinical Study of Use of Remdesivir and Tocilizumab in Severely Ill CO(epmc).pdf DeepDyve Pubget Overpricing